Alembic Pharmaceuticals Issues Duplicate Share Certificates Under SEBI Regulations

Alembic Pharmaceuticals Limited has announced the issuance of duplicate share certificates in compliance with Regulation 39(3) of SEBI's Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015. This action follows the approval of requests received from shareholders for the replacement of lost or misplaced share certificates.

Issuance of Duplicate Share Certificates
On July 31, 2024, Alembic Pharmaceuticals Limited, through its Registrar and Share Transfer Agent, Link Intime India Private Limited, processed the issuance of duplicate share certificates to two registered shareholders. This move was made in accordance with SEBI’s guidelines, ensuring that shareholders receive replacement certificates promptly and securely.

Key Details of the Duplicate Certificate Issuance

• Affected Shareholders:
  • Dhirubhai Gokalbhai Patel: Issued a duplicate certificate for 150 shares under folio number 0035274.
  • Ishverbhai Lallubhai Patel: Issued a duplicate certificate for 150 shares under folio number 0037632.
• Regulatory Compliance: The issuance of these duplicate certificates follows SEBI Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/8, dated January 25, 2022, which mandates the procedure for the replacement of lost or misplaced share certificates.
• Certificate Details: Each new certificate issued is in lieu of the old, with identical share quantities and paid-up value, ensuring that shareholder equity remains unaffected.

Importance of Compliance with SEBI Regulations

Alembic Pharmaceuticals Limited’s adherence to SEBI’s LODR Regulations ensures that the company maintains high standards of corporate governance and shareholder relations. By promptly addressing shareholder requests for duplicate certificates, the company reaffirms its commitment to transparency and regulatory compliance.

Next Steps for Shareholders

Shareholders who receive duplicate certificates are advised to check the details carefully and notify the company’s Registrar and Share Transfer Agent in case of any discrepancies. The company will continue to provide necessary support to ensure a smooth process for all concerned parties.